| 体内研究: |
Diethylcarbamazine citrate (250 mg/kg, 静脉注射, 单剂量) 在感染白化病的大鼠中可引起 mf 计数早期急剧下降,随后又增加。 Diethylcarbamazine citrate (50 mg/kg, 口服, 每周两次) 通过调节脂肪组织炎症改善高脂肪饮食诱导的肥胖小鼠的胰岛素抵抗。 |
| 参考文献: |
1. El-Shahawi GA, et al. Setaria equina: in vivo effect of diethylcarbamazine citrate on microfilariae in albino rats. Exp Parasitol. 2010 Dec;126(4):603-10. 2. Abdul-Razek N, et al. Enhancement of Anti-allergic Effect of Diethylcarbamazine Citrate in Asthmatic Mouse Model: Testing of Anti-drug Antibodies and Quercetin. Iran J Allergy Asthma Immunol. 2020 Aug 25;19(4):373-385. 3. Abdel-Latif M. Diethylcarbamazine citrate ameliorates insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. Int Immunopharmacol. 2015 Dec;29(2):607-612. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.555 ml |
12.774 ml |
25.548 ml |
| 5 mM |
0.511 ml |
2.555 ml |
5.11 ml |
| 10 mM |
0.255 ml |
1.277 ml |
2.555 ml |
| 50 mM |
0.051 ml |
0.255 ml |
0.511 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |